Cincinnati Children’s Partners with FDNA to Help Children with PACS1 Syndrome

September 26, 2017

Cincinnati Children’s Hospital & FDNA – “Today, Cincinnati Children’s Hospital Medical Center announced the results of its new collaboration with Boston-based FDNA to accelerate the identification of PACS1 Syndrome in affected patients.

PACS1 is an extremely rare genetic disease with roughly 30 confirmed cases globally. It results in mobility, motor and cognitive delays and disabilities. Through the collaboration and collection of syndrome data, Face2Gene can now recognize and detect associations between PACS1-related facial characteristics and other phenotypes and genes.

“According to recent studies, approximately one-third of all patients admitted to children’s hospitals have genetic disorders. Many of these are quite rare and traditionally can only be diagnosed when recognized by an astute clinician,” said Robert Hopkin, MD, in the Division of Human Genetics at Cincinnati Children’s. “PACS1 is typically confirmed using genetic testing, and now Face2Gene can help clinicians recognize the PACS1 phenotype earlier—especially where genetic testing is unavailable.”

Read More

Share this article

Most popular news

Related articles

AI in genetic diagnosis

The Evolution of FDNA’s technology: An Interview with Aviram Bar Haim

Analyzing facial features has long been a vital step in diagnosing genetic syndromes. In recent years, AI-driven technologies have transformed this process, making it more efficient and accurate. Leading this innovation is Face2Gene, an advanced AI platform that leverages machine learning to assist clinicians in identifying genetic disorders. To explore the development of this groundbreaking […]

Continue reading
Genetic Research in Africa: An Interview

Genetic Research in Africa: An Interview with Dr. Aime Lumaka

Dr. Aime Lumaka, a distinguished geneticist from the Democratic Republic of Congo, is at the forefront of advancing genetic research across Africa. As a pivotal figure in the Deciphering Developmental Disorders in Africa (DDD-Africa) initiative and the Principal Investigator of the African Rare Diseases Initiative (ARDI), Dr Lumaka is leading efforts to evaluate clinical exome sequencing in […]

Continue reading